A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to investigate the efficacy and safety of FK199B (Zolpidem MR Tablet) in patients with insomnia by a randomized, double-blind, group-comparison study using zolpidem (Myslee) as a comparative drug
Condition or disease
Sleep Initiation and Maintenance DisordersSleep Disorders
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
20 Years to 64 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Clinical diagnosis of nonorganic insomnia.
Must be able to swallow tablets
Allergic reactions to zolpidem (Myslee)
Serious cardiac disorders; Serious hepatic impairment; Serious renal diseases, etc.